The Multiple Sclerosis Competitive Landscape The Multiple Sclerosis Competitive Landscape Continue readingThe Multiple Sclerosis Competitive Landscape Comments closed
Trillium Therapeutics: a Pure-Play on CD47 as an Immuno-Oncology Target Trillium Therapeutics: a Pure-Play on CD47 as an Immuno-Oncology Target Continue readingTrillium Therapeutics: a Pure-Play on CD47 as an Immuno-Oncology Target Comments closed
Small-Molecule Strategies Aimed at Degrading Cellular Proteins Small-Molecule Strategies Aimed at Degrading Cellular Proteins Continue readingSmall-Molecule Strategies Aimed at Degrading Cellular Proteins Comments closed
Strategies to Enhance Patient Responses to Checkpoint Inhibitors Strategies to Enhance Patient Responses to Checkpoint Inhibitors Continue readingStrategies to Enhance Patient Responses to Checkpoint Inhibitors Comments closed
Epizyme Provides Update on Tazemetostat (EPZ-6438) Phase I data Epizyme Provides Update on Tazemetostat (EPZ-6438) Phase I data Continue readingEpizyme Provides Update on Tazemetostat (EPZ-6438) Phase I data Comments closed
Epizyme Inc. and the Orphan Drug with Mainstream Potential Epizyme Inc. and the Orphan Drug with Mainstream Potential Continue readingEpizyme Inc. and the Orphan Drug with Mainstream Potential Comments closed
